Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Appointed director

OptiNose, Inc. (OPTN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 144 Form 144 - Report of proposed sale of securities:
08/18/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/10/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Second Quarter 2023 Financial Results and Operational Updates Optinose Reports Second Quarter 2023 Financial Results and Operational Updates Optinose Reports Second Quarter 2023 Financial Results and Operational Updates",
"Q2 2023 30.1 30.9 Q2"
07/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million"
06/09/2023 4 HELTON SANDRA L (Director) has filed a Form 4 on OptiNose, Inc.
Txns: Granted 53,500 options to buy @ $1.18, valued at $63.1k
06/09/2023 4 Bednarski Eric (Director) has filed a Form 4 on OptiNose, Inc.
Txns: Granted 53,500 options to buy @ $1.18, valued at $63.1k
06/09/2023 4 Dempsey Kyle (Director) has filed a Form 4 on OptiNose, Inc.
Txns: Granted 53,500 options to buy @ $1.18, valued at $63.1k
06/09/2023 4 FLETCHER R JOHN (Director) has filed a Form 4 on OptiNose, Inc.
Txns: Granted 53,500 options to buy @ $1.18, valued at $63.1k
06/09/2023 4 GROENHUYSEN WILHELMUS CM (Director) has filed a Form 4 on OptiNose, Inc.
Txns: Granted 53,500 options to buy @ $1.18, valued at $63.1k
06/09/2023 4 Heyman Tomas J. (Director) has filed a Form 4 on OptiNose, Inc.
Txns: Granted 53,500 options to buy @ $1.18, valued at $63.1k
06/09/2023 4 Owen Catherine E. (Director) has filed a Form 4 on OptiNose, Inc.
Txns: Granted 53,500 options to buy @ $1.18, valued at $63.1k
05/16/2023 4 Avista Capital Partners II GP, LLC (10% Owner) has filed a Form 4 on OptiNose, Inc.
Txns: Disposed of 10,102,707 shares @ $0
Disposed of 3,328,648 shares @ $0
Disposed of 807,995 shares @ $0
Acquired 48,370 shares @ $0
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports First Quarter 2023 Financial Results and Operational Updates Optinose Reports First Quarter 2023 Financial Results and Operational Updates Optinose Reports First Quarter 2023 Financial Results and Operational Updates",
"Q1 2023 29.5 30.4 Q1"
05/04/2023 8-K Quarterly results
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/17/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
03/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/07/2023 10-K Annual Report for the period ended December 31, 2022
03/07/2023 8-K Investor presentation, Quarterly results
Docs: "Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights",
"2 0 2 3 EXHIBIT 99.2"
02/14/2023 SC 13G/A GREAT POINT PARTNERS LLC reports a 10% stake in OPTINOSE, INC.
02/14/2023 SC 13D/A MVM Partners, LLC reports a 14.9% stake in OPTINOSE, INC.
02/09/2023 SC 13G/A FMR LLC reports a 13.3% stake in OPTINOSE INC
02/02/2023 4 Mahmoud Ramy A (CEO) has filed a Form 4 on OptiNose, Inc.
Txns: Granted 336,135 shares @ $0
Granted 549,202 options to buy @ $1.74, valued at $955.6k
01/31/2023 8-K Appointed a new director
Docs: "AMENDED AND RESTATED EMPLOYMENT AGREEMENT",
"SEPARATION AGREEMENT AND GENERAL RELEASE",
"Main +1 267 364 3500 Fax +1 267 395 2119 www.optinose.com",
"Optinose Announces CEO Transition and Business Update Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors"
01/19/2023 SC 13G/A KRUTTSCHNITT THEODORE H III has filed a Schedule 13D for OptiNose, Inc.
01/17/2023 4 Marino Michael F III (Chief Legal Officer & Corp Sec) has filed a Form 4 on OptiNose, Inc.
Txns: Sold 5,241 shares @ $1.77, valued at $9.3k
01/17/2023 4 Mahmoud Ramy A (President and COO) has filed a Form 4 on OptiNose, Inc.
Txns: Sold 8,148 shares @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy